Physician profile
Shams Tabrez
NPI 1215902184
$2,289.45
in general payments reported to CMS, 2019-2025
22 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.69 · 2021: $143 · 2022: $103 · 2023: $78.86 · 2024: $683 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900 · Education: $44.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.89 |
| Education | $44.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.59 | 2019-2025 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.07 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Regeneron Healthcare Solutions, INC. | $191.32 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.47 | 2025 | Entyvio, Eohilia |
| Evoke Pharma, INC. | $103.24 | 2022-2024 | Gimoti |
| Qol Medical, LLC | $96.39 | 2019-2025 | Sucraid |
| Boston Scientific Corporation | $71.46 | 2024 | |
| Aimmune Therapeutics, INC. | $66.19 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $59.09 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $52.78 | 2024-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $50.93 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $47.98 | 2024-2025 | Suflave |
| Madrigal Pharmaceuticals | $41.58 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $31.44 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $30.06 | 2025 | Ibsrela |
| Novo Nordisk INC | $21.36 | 2025 | Wegovy |
| Medtronic, INC. | $17.93 | 2021 | |
| Echosens North America, INC. | $17.90 | 2025 | Fibroscan |
| Tela Bio, INC. | $15.56 | 2024 | Ovitex 2s |
| Covidien LP | $14.49 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shams Tabrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.